Industry News
Protein could predict women who will miscarry
A protein found in the placenta of pregnant women could be used to predict whether they will miscarry their babies, Monash University/Monash Medical Centre researchers working with scientists at St Vincent's Hospital, Sydney, have found.
[ + ]Australian Innovation at the Speed of Light
CSIRO has announced its commitment of $5M to the Australian Synchrotron facility (AS) heralding its participation in the $206M facility as a Foundation Partner.
[ + ]Macquarie supports Australian involvement in space exploration
Macquarie University's Australian Centre for Astrobiology (ACA) has supported a recommendation by a new consortium of Australian space-related organisations that the Federal Government help maximise Australia's involvement in the future of space exploration by setting up an Australian space agency.
[ + ]RMIT researchers tackle deadly plant
RMIT researchers are investigating a poisonous weed that threatens native Australian animals and livestock and could pose a serious public health risk.
[ + ]Green light for new plant technology
Brilliant green turf all-year round, needing less maintenance and mowing, could soon be available through technology developed at The University of Queensland.
[ + ]BresaGen goes into voluntary administration
Australian biotechnology veteran BresaGen (ASX:BGN) has gone into voluntary administration. [ + ]
Bionomics reports healthy bank balance
Adelaide biotech Bionomics (ASX:BNO) has reported that it had nearly AUD$5 million in the bank at the end of the December 2003 quarter, giving it enough cash for at least two years at its current burn rate. [ + ]
CSL, Chiron move to Phase II hep C vaccine trial
The hopes of hundreds of thousands of people around the world chronically infected with hepatitis C virus could be riding on an Australian clinical trial of a new, potentially life-saving vaccine being jointly developed by US-based Chiron Corporation and Melbourne pharmaceutical company CSL (ASX:CSL). [ + ]
Fewer farmer objections to GM crops
A national survey of Australian farmers' views on genetically modified (GM) crops has identified a marked shift in sentiment during the past 12 months, with fewer farmers now opposed. [ + ]
Biotron wins Start grant for virus blocker trials
Canberra biotechnology company Biotron (ASX:BIT) has been offered a $1.66 million Commonwealth R&D Start grant to begin clinical development and testing of novel compounds designed to disrupt replication of the AIDS virus. [ + ]
UNSW spin-off Biosignal to list in reverse takeover
Biosignal, a spin-off from the University of NSW, is to list on the ASX in late March through a reverse takeover of CTI Communications (ASX:CTC), a telecommunications services company. [ + ]
Public to get another say on xenotransplantation
The National Health and Medical Research Council has kicked off a second round of public comment on its draft guidelines for xenotransplantation research, and will run a series of community consultation meetings in capital cities in February. [ + ]
Xeno virus no problem: researcher
A new US finding, that transplanted human cells can form pig-human hybrid cells in foetal pigs, does not present a new hazard for transplants of humanised pig organs or cells into humans, according to a leading Melbourne xenotransplantation researcher. [ + ]
Patch vaccines may increase autoimmune disease risk
Australian researchers have shown in a mouse model that a bacterial toxin used as an immune-stimulating agent in some vaccines may increase the risk of developing autoimmune disease, where the immune system reacts against the body's own proteins. [ + ]
pSivida to trade on German exchanges
Perth-based nanotech company pSivida (ASX:PSD) will soon commence trading on the German stock exchanges in Berlin, Munich and Stuttgart after meeting all listing requirements, the company has announced. [ + ]
